12
September 2024
Avacta Group
plc
("Avacta"
or the "Company")
Notice of
Results
Investor Presentation via
Investor Meet Company
Avacta Group plc (AIM: AVCT), a life
sciences company developing innovative, targeted cancer treatments
and powerful diagnostics, will announce its unaudited interim
results on 30 September 2024 for the six months ended 30 June
2024.
Christina Coughlin, MD, PhD,
Avacta's CEO, will discuss the results and the Company's
operational and clinical progress via the Investor Meet Company
platform on 30 September 2024 at 11:00 BST.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 29
September 2024, 09:00 BST, or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet AVACTA GROUP
PLC via:
https://www.investormeetcompany.com/avacta-group-plc/register-investor.
Investors who already
follow Avacta on the Investor Meet Company platform will
automatically be invited.
The Company will also post its
results presentation on its website at the following
page: https://avacta.com/investors/documents-presentations.
-Ends-
For
further information from Avacta Group plc, please
contact:
|
Avacta Group plc
Christina Coughlin, Chief Executive
Officer
Michael Vinegrad, Group
Communications Director
|
Tel: +44
(0) 1904 21 7070
www.avacta.com
|
|
Peel Hunt (Nomad and Broker)
James Steel / Chris Golden / Patrick
Birkholm
|
www.peelhunt.com
|
|
ICR
Consilium
Mary-Jane Elliott / Jessica Hodgson
/ Sukaina Virji
|
avacta@consilium-comms.com
|
About Avacta Group plc - www.avacta.com
Avacta Group is a UK-based life
sciences company focused on improving healthcare outcomes through
targeted cancer treatments and diagnostics.
Avacta Therapeutics: a clinical
stage oncology biotech division harnessing proprietary therapeutic
platforms to develop novel, highly targeted cancer
drugs.
Avacta Diagnostics focuses on
supporting healthcare professionals and broadening access to
diagnostics.
Avacta has two proprietary
platforms, pre|CISION™ and Affimer®.
The pre|CISION™ platform is a highly
specific substrate for fibroblast activation protein (FAP) which is
upregulated in most solid tumours compared with healthy tissues.
The pre|CISION™ platform harnesses this tumour specific protease to
activate pre|CISION™ peptide drug conjugates and pre|CISION™
antibody/Affimer® drug conjugates in the tumour microenvironment,
reducing systemic exposure and toxicity, allowing dosing to be
optimised to deliver the best outcomes for patients.
The lead pre|CISION™ programme
AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase
1 studies. It has shown an improvement in safety and tolerability
in clinical trials to date compared with standard doxorubicin and
preliminary signs of clinical activity in multiple
patients.
To register for news alerts by email
go to www.avacta.com/investor-news-email-alerts